

MEDIA RELEASE
16 March 2022

New supply agreements with German health insurance funds provide greater access to Canpharma medicines

Health House International Ltd (ASX:HHI) (Health House or the Company, together with the entities it controls **the Group**), is pleased to advise it's wholly-owned subsidiary CanPharma GmbH ("CanPharma") has continued its strategy to enter into preferred supplier agreements with German statutory health insurance (SHI) funds, securing agreements with 5 funds to date.

CanPharma announced today its latest agreement with Techniker Krankenkasse ("TKK"), the largest German statutory health insurance fund that represents more than 10 million insured individuals. This new agreement brings the total number of patients that are covered by SHI funds with preferred supplier agreements with CanPharma to over 35 million, representing almost 50% of the total number of insured Germans.



CanPharma Chief Executive Officer, and Health House Executive Director, Dr Henrik Sprengel said Canpharma is encouraged by the continually positively changing perception of medicinal cannabis.

"Having public insurance companies endorse medicinal cannabis as a valid treatment option is a sign of this positive progress and we are optimistic that this will lead to a higher reimbursement quota and increase in the number of German patients treated with medicinal cannabis." **Dr Sprengel** said.

CanPharma is one of the few German cannabis companies eligible for the schemes due to its GMP manufacturing licence. Under the agreements, CanPharma will be a preferred supplier to the funds for a selection of its CanPharma branded flowers and extracts.

When doctors prescribe medicinal cannabis products for new patients that are insured with one of the affiliated insurance funds, the doctors are required to choose a product from a shortlist if the patients are to be reimbursed.

"We are delighted to see that CanPharma is showing its leadership on relationships with insurers, key stakeholders in the German market. We see this as cementing our position for the future where medicinal cannabis becomes mainstream and insurers give it more focus. The requirement for GMP manufacturing licence gives us an advantage compared to most players" said **Health House Chief Executive Officer, David Attwood.**

In Germany public Healthcare is provided through a Statutory Health Insurance (SHI), such as the TKK, that cover 90% of the population, with the remainder being covered by private health insurance companies.

CanPharma now has agreements with the following companies and funds:

- GWQ Service Plus AG, a company that represents 47 German statutory health insurance funds covering approximately 8 million individuals, commenced January 2022;
- IKK Classic, a German SHI fund covering more than 3 million individuals, commenced February 2022;
- Kaufmännische Krankenkasse, a German SHI fund covering 1.6 million individuals, commenced February 2022;
- SPECTRUM K Service Plus AG, a company that represents 22 German public health insurance funds that cover around 10 million individuals, commenced February 2022; and
- Techniker Krankenkasse, a German SHI fund that represents more than 10 million insured individuals commencing April 2022.

Please refer to [ASX Announcement 16 March](#) for further details.

About Health House

Health House International and the entities it controls (**the Group**) is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences. The Group supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe. The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.

For more information, please visit www.healthhouse.com.au

Address

Level 3
101 St Georges Tce
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: admin@healthhouse.com.au
W: www.healthhouse.com.au

Contact

David Attwood
Chief Executive Officer
David.attwood@healthhouse.com.au

David Wheeler

Chairman
david@pathwayscorporate.com.au